Because APE1 loss modulates sensitivity to replication stress-inducing agents like cisplatin rather than hormonal therapies, its impact on survival may be less pronounced in BRCA2 mutant breast cancer settings. This evidence concerns the gene APEX1 and breast carcinoma.